Multicentre Clinical Trial on Moxonidine Hydrochloride for Treatment of Hypertension

宋以信,吴树燕,孙宁玲,余霞君,刘肇禧,王军英,杜雪萍,梅巍,毛树森

DOI: https://doi.org/10.3969/j.issn.1001-6821.2003.01.002

2003-01-01

Abstract:OBJECTIVE: To evaluate the effect and safety of domestic moxonidine hydrochloride on mild to moderate hypertension METHOD: This multicentre clinical trial used clonidine as control, and it was single blind and randomly parellel. There were 302 patients in moxonidine group, (101 of them were compared with clonidine group, the other 201 were set as open treatment group.) and there were 100 patients in clonidine group. The start dose were 0.2 and 0.15mg· d-1, respectively. After two weeks, if the blood pressure was higher than 140/90 mmHg, the doses were added to 0.4 and 0.3mg · d-1, respectively. The total course of treatment was 4 weeks. Patients who were reactive to moxonidine continued to use it for 6 months, and 19 of them were carried out ambulatory blood pressure monitoring before and after treatment, then analysed with T/P ratio. RESULT: Blood pressure began to decline in the first week of treatment. After 4 weeks,the mean systolic and diastolic blood pressure in seat of moxonidine group declined 12.1%-12.6% and 12%-13.5%, respectively. And those of control group declined 12.9% and 13.4%. The total efficacy rates of the two kinds of drug were 82.5% and 74%. There was no remarkable difference between the clinical efficacy rates of the two kinds of drug . Six months treatment with moxonidine could maintain its anti-hypertensive effect. The frequent adverse reaction of moxonidine is dizziness,drowsiness and inertia, et al. But they were all gently, the patients had better tolerance. And moxonidine had no side effect on biochemistry exams. CONCLUSION: Moxonidine has affirmed effect on mild to moderate hypertension, with little side effects, good patients tolerance. Moxonidine is better than clonidine by total clinical evaluation.